Endo to Acquire Boca Pharmacal

Article

Endo will acquire Boca Pharmacal in multimillion dollar deal.

The specialty pharmaceutical company, Endo Health Solutions, Qualitest subsidiary has agreed to acquire Boca Pharmacal, a specialty generics company, for $225 million.

Boca Pharmacal is a specialty generics company that focuses on niche areas, commercializing and developing products in categories that include controlled substances, semisolids, and solutions. The deal is expected to close before the end of 2013, subject to standard regulatory requirements.

Source: Endo Health Solutions

Recent Videos
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content